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a b s t r a c t
Recent studies suggest that immune activation and cytokines, such as IL-18, are involved in depression. 
IL-18 is expressed in brain and is increased in patients with moderate to severe depression. In this study 
we aim to evaluate the role of IL18-607C > A and IL18-137G > C promoter polymorphisms in antidepressant 
treatment phenotypes, speciﬁcally relapse and treatment resistant depression (TRD). We genotyped the 
referred polymorphisms in a subset of 80 MDD patients followed at Hospital Magalhães Lemos, Portugal, 
within a period of 27 months. Patients carrying IL18-607 CA or AA genotypes were signiﬁcantly more 
prone to relapse after AD treatment and present a signiﬁcantly lower time to relapse than patients car-
rying CC genotype. Similarly, patients carrying IL18-137 GC or CC genotypes have a signiﬁcantly higher 
risk of relapse and display relapse signiﬁcantly earlier than the ones carrying GG genotype. Due to the 
low number of IL18-607 CC and IL18-137 GG in the relapse subgroup (n = 3 and n = 5, respectively), results 
were validated by bootstrapping analysis, and remained signiﬁcant. No association was found between 
the evaluated genetic polymorphisms and TRD. IL18 peripheral mRNA levels were upregulated in IL18-607 
CA or AA carriers. This preliminary report indicates that IL18-607C > A and IL18-137G > C genetic polymor-
phisms seem to inﬂuence depression relapse after antidepressant treatment in our subset of depressed h i g h l i g h t s
• IL18-607C>A and IL18-137G>C polymorphisms were associated with t
• IL18 peripheral mRNA levels were found upregulated in IL18-607 CA/A
• No association was found between SNPs and the development of TRD.
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patients, and may possibly contribute to the disregulated IL-18 levels found in patients with depression. he risk of depression relapse.
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reatment response is oftenvariable.Only a thirdof patients treated
ith AD achieve full remission, and from thesemany suffer relapse.
dditionally, a substantial proportion of patients fail to respond to
ny antidepressants, displaying a Treatment Resistant Depression
TRD) phenotype [2].
Increasing evidences point towards the involvement of the
mune system, and in particular cytokines, in the development
nd progression of depression [3]. Additionally, several evidences
how that pro-inﬂammatory cytokines, including Interleukin (IL)-
8, have been reported to be elevated in patients with MDD
4,5]. IL-18, and its receptors, are expressed in the central nervous
ystem (CNS) where they participate in the neuroinﬂamma-
ory/neurodegenerative processes and also inﬂuence homeostasis
nd behaviour [6]. IL18 gene transcripts were identiﬁed, by RT-
CR, in a variety of brain regions including the hippocampus, the
ypothalamus and the cerebral cortex [7]. Several in vivo studies,
und IL-18protein in thepituitary gland, ependymal cells, theneu-
ons of the medial habenula, in Purkinje cells, and in astrocytes in
he cerebellum [8]. In addition, it was demonstrated in vitro that
icroglia and astrocytes can produce IL-18 [9].
Moreover, several AD have been shown to suppress pro-
ﬂammatory cytokine production and to release endogenous
nti-inﬂammatory cytokines [10]. Likewise, in healthy rats, chronic
ntidepressant treatments affected the hypothalamic expression
f members of IL-18 system [11]. Taking in consideration these
bservations, it is plausibly to postulate that the variability of
D therapeutic effect may be modulated by differential expres-
ion of cytokines, among these, IL-18. Functional single nucleotide
olymorphisms (SNP) in the promoter region of IL-18 gene, such
s rs1946518 and rs187238, are known to alter its transcrip-
ional activity. Rs1946518 polymorphism, involves a change from
ucleotide C to nucleotide A at position −607, and it is thought
o disrupt a potential cAMP-responsive element binding protein
CREB) site [12]. Similarly, rs187238polymorphism, locatedatposi-
ion−137, involves a change fromnucleotideG to nucleotide C, and
recognised to affect the H4TF-1 nuclear factor binding site [12].
IL18 genetic polymorphisms have been associated with dis-
inct clinical conditions, including depressive symptoms in stroke
atients [13], and onset of depression in patients previously
xposed to stressful-life events [14].
In spite of the fact that several antidepressants drugs are avail-
ble in the clinical setting, a wide fraction of patients fail to remit
o treatment, present relapse or display TRD. Most pharmacoge-
etic studies regarding antidepressant treatment outcome in MDD
atients are typically 8–12 weeks long [2], not exploring remis-
ion or relapse phenotypes, which are clinical important outcomes.
entifying patients at risk of relapse, or TRD, using biomarkers
ould possibly have direct impact on individualizing AD therapy.
Despite the recent implications of IL-18 in depression, IL18
eneticpolymorphismsneverbeenstudied in the contextof antide-
ressant treatmentphenotypes, including remission and relapse. In
his circumstance, we aim to evaluate the role of IL18-607C>A and
18-137G>C functional polymorphisms in antidepressant treat-
ent response phenotypes.
2. Methods
. Introduction
Major Depressive Disorder (MDD) is a highly prevalent chronic
sychiatric condition associated with a signiﬁcant morbidity and
ortality [1]. Antidepressant drugs (AD) arewidely used; however,2.1. Patients
The study cohort included 80 participants monitored in a 27
onths-follow-up at Hospital Magalhães Lemos (HML), as we pre-
iouslydescribed [15,16]. Brieﬂy, patientswereevaluated formajor
epression using the Structured Clinical Interview for DSM Axis I
isorders (SCID-I), and for personality disorders using the Axis II
isorders (SCID-II). Severity of the depressive symptoms was eval-uated with Beck Depression Inventory (BDI), a cut-off of 20 wa
used as the point for entry into this study. Exclusion criteria ha
been described in Santos, et al. (2015) [15]. Patient’s treatment fo
lowed the Major Depressive Disorder treatment algorithm of Texa
Medication Algorithm Project (TMAP) [17]. Initial medication wa
selected clinically from the medicines included in the ﬁrst line o
approach of the TMAP. The effectiveness of the therapy (admini
tered after at least 6 weeks and at adequate doses according to th
TMAP protocol) was assessed as the change in the Beck Depre
sion Inventory (BDI) score. Remission was deﬁned as BDI score les
than 10 after 6 weeks of at least one single adequate antidepre
sant treatment and absence of criteria of MDD according to SCID-
Antidepressant medication could be changed for nonresponse o
intolerably as per the TMAP protocol. ‘Treatment resistant depre
sion’ (TRD) was recorded when the patient failed to reach a BD
score less than 10 and present criteria of MDD according to SCID-
after at least two adequate antidepressant treatments with diffe
ent drugs within the current episode. Relapse was deﬁned as an
depressive episode, upon remission, during the 24-month follo
up. Bad Prognosis was considered when patient displayed TRD o
relapsed. The studywas approved by the ethical committee of Ho
pital Magalhães Lemos, and written informed consent according t
“Declaration of Helsinki” was obtained from each individual afte
explanation of the study.
2.2. DNA extraction and IL18-607C>A and IL18-137G>C
polymorphism analysis
Peripheral blood samples were collected into ethylened
aminetetraacetic acid (EDTA) containing tubes, and the genom
DNA was isolated according to the manufacturer’s instruction
with a commercial kit (E.Z.N.A. − Omega Bio-tek, Norcross, USA
and stored at −20 ◦C.
The IL18-607C>A and IL18-137G>C polymorphismswere dete
mined using a Sequenom MassARRAY system (San Diego, CA, USA
as we previously described [15]. Sequenom Assay Design 3.1 sof
ware was used to design the primers for polymerase chain reactio
(PCR) ampliﬁcation and single base extension assays (Sequenom
San Diego, CA, USA). Genotyping data was read blindly to th
study endpoint. For quality control, 10% of the samples were ran
domly selected for a second analysis and 100% of concordance wa
observed.
2.3. RNA extraction and IL-18 mRNA expression analysis
To correlate IL18 mRNA expression with the different genotyp
groups, a total of 38 peripheral blood samples were randomly co
lected after completion of the 27 month follow up. This patient
subgroup included 21 remitters, 9 relapsed and 8 patients wit
TRD. Age, gender and the last psychotropic drugs prescribed prio
to blood recovery were not statistically different among these sub
groups of patients (results not shown). Whole blood was collecte
between 8.30 and 12.30 a.m., and RNA was isolated from bloo
leucocytes using “Tripure” reagent (Roche Diagnostics GmbH
Mannheim, Germany), according to the manufacturer’s instruc
tions. RNA’s purity and quantity were determined in a “Nanodrop
equipment (ND1000, Nano Drop Technologies Inc. Wilmingto
DE, USA), by measuring OD at 260/280nm and 260nm respec
tively. The “HighCapacity cDNAReverseTranscriptionKit” (Applie
Biosystems, Foster City, CA) was used to reversely transcribed u
to 2g of total RNA to cDNA, with random primers. TaqMan® Gen
Expression Master Mix, primers and probes provided by Applie
Biosystems were used for Real-time PCR ampliﬁcation of cDN
samples, which was performed in a StepOneTM Real-Time PCR
System (Applied Biosystems). Expression of IL18 was measured
with TaqMan expression assay (ID: Hs01038788 m1) from Applied
Table 1
Clinical and general characteristics of patients.
IL18-607C/A P IL18-137G/C p
Characteristics Patients (n =80) CC (n=31) CA/AA (n=49) GG (n=44) GC/CC (n=36)
Age, years mean (SD) range 40.48 (11.06)
18.0–60.0
43.06 (9.90)
24.0–57.0
38.84 (11.54)
18.0–60.0
0.096 42.54 (10.68)
18.0–60.0
37.94 (11.14)
19.0–60.0
0.064
Gender, female n (%) 59 (73.8) 20 (64.5) 39 (79.6) 0.135 29 (65.9) 30 (83.3) 0.078
School attendance, years mean (SD) range 9.63 (3.90)
4.0–20.0
8.90 (3.74)
4.0–17.0
10.08 (3.97)
4.0–20.0
0.190 9.27 (3.47)
4.0–17.0
10.06 (4.38)
4.0–20.0
0.386
Baseline BDI Score, mean (SD), range 27.81 (7.40)
20.0–48.0
27.06 (7.60)
20.0–48.0
28.29 (7.30)
20.0–46.0
0.476 28.18 (7.94)
20.0–48.0
27.36 (6.77)
20.0–45.0
0.625
Last treatment prescribed, n (%)
SSRIs 43 (53.8) 16 (33.3) 27 (32.9) 0.986 23 (35.4) 20 (30.8) 0.628
SNRIs 8 (10.0) 3 (6.3) 5 (6.1) 6 (9.2) 2 (3.1)
Tricyclic drugs 36 (45.0) 12 (25.0) 24 (29.3) 15 (23.1) 21 (32.3)
Benzodiazepines 25 (31.3) 9 (18.8) 16 (19.5) 12 (18.5) 13 (20)
Mood stabilizers 9 (11.3) 4 (8.3) 5 (6.1) 4 (6.1) 5 (7.7)
5 (6.
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iOther drugs 9 (11.3) 4 (8.3)
SRIs − Selective serotonin recapture inhibitors. SNRIs—Serotonin and norepinephr
iosystems. Selection of the reference gene for data normalization
as performed among a set of 4 housekeeping genes, ACTB, GAPDH,
PRT and 18S, andGAPDHwas chosen since it present higher stabil-
ty among the MDD samples (data not shown). Relative expression
alues were obtained through the mean cycle threshold deviation
f CA+AA genotype group, using the CC genotype group as control
or IL18-607A>C,normalizedby reference transcripts (2−Ct). The
amecalculationwasperformed for IL18-137G>Cgenetic polymor-
hism comparing the GC+CC group with the control GG group. The
EST 2009 Software (ver.2.0.13) was used for the relative expres-
ion analysis [18]. The ampliﬁcation reaction efﬁciency for each
ssay was above 95% (as determined by the manufacturer).
.4. Statistical analysis
Statistical analysis was performed with IBM®SPSS® (ver.22.0)
nd Epi Info (ver.6.04a). Chi-square (2) analysis was used to com-
are the categorical variables with a 5% level of signiﬁcance. The
ssociation between genotypes and the risk of developing the eval-
ated phenotypes was determined by Odds ratio (OR) with a 95%
onﬁdence interval (CI). Fisher’s Exact Testwas used for tables con-
aining cellswith less than 5 individuals. Bootstrappingwas used to
alidate the associations, and p values were determined based on
000 bootstrap samples. Correlation between genotypes and time
o relapse was accomplished with Kaplan-Meier survival curves,
hich were compared by Log-rank statistical test. The linkage dis-
quilibrium (LD) between loci was measured using Lewontin’s D’
D’) and r2, and the haplotype frequency were determined with
NP & Variation Suite (SVS) 7 free trial (Golden Helix) software. In
ddition, to correct formultiple comparison testing, adjusted P val-
es were determined using the false discovery rate (FDR) method.
egarding gene expression, Pair Wise Fixed Reallocation Randomi-
ation Test©, calculated by REST software, was used to determined
he relative gene expression between genotype groups [18]. A
osteriori power analysis was performed using Quanto software
ver.1.0;http://hydra.usc.edu/gxe). The magnitude of our sample is
ppropriate to detected association effects of at least 2.5 OR for the
tudied SNPs, with a statistical power of 80%, and a maximal 5%
xperiment-wise type I error.
. Results.1. Antidepressant response phenotypes
Demographic and clinical variables of the cohort are presented
n Table 1. This cohort was mainly constituted by females (73.8%),1) 5 (7.7) 4 (6.1)
uptake inhibitors.
with a mean age of 40.48 (S.D. 11.06), a mean of 9 years of school
(S.D. 3.90) and a mean BDI baseline of 27.81 (S.D. 7.4). The phe-
notype remission was reported in 61 patients (76.2%), and 16
remitters (20.0%) presented relapse during the follow-up period.
Furthermore, 19 patients (23.8%) presented TRD. Bad Prognosis
group, which comprised patients presenting relapse or TRD, rep-
resented 43.8% (35 patients) of the sample. In order to identify
potential confounders we performed an univariate analysis com-
paring age, gender, school attendance, baseline BDI and the last
treatment prescribed, among the different genotypes of the evalu-
ated polymorphisms. None of the sociodemographic and clinical
variables were signiﬁcantly different in each genotype groups
(Table 1).
3.2. Genotype frequencies of IL18 polymorphisms and treatment
outcome
The genotype distribution of IL18-607C>A and IL18-137G>C
polymorphisms were evaluated among the different treatment
response phenotypes (Table 2). No signiﬁcant deviations from
the Hardy–Weinberg equilibrium proportions were observed for
both SNPs (P >0.05). We found that patients carrying IL18-607
CA/AA genotypes are more prone to relapse after AD treatment
(OR=4.145; 95% CI: [1.038–16.555]; Fisher p=0.043; Fisher FDR
corrected p=0.043) and present a lower time to relapse than
patients carrying CC genotype (Fig. 1A; 69 vs 115 weeks, p=0.019,
Log-rank test). We also observed that patients carrying IL18-137
GC/CC genotypes have a higher risk of relapse (OR=3.988; 95%
CI: [1.176–13.516]; p=0.022; FDR corrected p=0.043) and display
relapse earlier than the ones carrying GG genotype (Fig. 1B; 64
vs 112 weeks, p=0.006, Log-rank test). Due to the small sample
size, especially the low number of patients in the subgroup of CC
and GG genotypes that present relapse, we validated the results by
bootstrapping, and these ﬁndings remained statistically signiﬁcant
(Table 2). No association was found between the evaluated genetic
polymorphisms and TRD. Regarding the phenotype bad prognosis,
individuals carrying CA/AA genotype for IL18-607 present approxi-
mately a 3-fold risk of developing this phenotype, when comparing
with the ones harboring CC genotype (Table 2).
3.3. IL18 haplotypes and treatment outcomeTo estimate the combined inﬂuence of IL18 polymorphisms
in the risk of relapse, haplotype analysis was carried out. A
total of 3 different haplotypes were identiﬁed using the SVS
software (Table 3). Haplotype analysis revealed an association
Fig. 1. Effect of IL18 polymorphisms in time to relapse in MDD patients. Kaplan-Meier analysis was used to evaluate time to relapse between (A) IL18-607 CC and CA+AA
carriers and (B) IL18-137 GG and GC+CC carriers. Comparison performed by Log-rank test ((A) p=0.019; (B) p =0.006). +censored “IL18-607 CC carriers” or “IL18-137 GG
carriers”;  censored “IL18-607 CA or AA carriers” or “IL18-137 GC or CC carriers”.
Table 2
Overview of association between genotypes under investigation and outcomes.
Genotypes Frequency
IL18-607 Rs1946518C>A IL18-137 rs187238G>C
No Yes OR CI 95% P value P value* No Yes OR CI 95% P value P value*
N % N % N % N %
Relapsed CC 22 48.9 3 18.7 1.0 Referent – – GG 29 64.4 5 31.2 1.0 Referent – –
CA 18 40.0 11 68.8 4.481 [1.083–18.549] 0.060a 0.038 GC 13 28.9 9 56.3 4.015 [1.123–14.356] 0.027 0.032
AA 5 11.1 2 12.5 2.933 [0.383–22.463] 0.296a 0.198 CC 3 6.70 2 12.5 3.867 [0.510–29.304] 0.213a 0.094
A carrier 23 51.1 13 81.3 4.145 [1.038–16.550] 0.043a 0.023 C carrier 16 35.6 11 68.8 3.992 [1.176–13.916] 0.022 0.019
TRD CC 25 41.0 6 31.5 1.0 Referent – – GG 34 55.7 10 52.7 1.0 Referent – –
CA 29 47.5 9 47.4 1.293 [0.404–4.138] 0.665 0.664 GC 22 36.1 7 36.8 1.082 [0.358–3.266] 0.889 0.907
AA 7 11.5 4 21.1 2.381 [0.522–10.860] 0.410a 0.253 CC 5 8.20 2 10.5 1.36 [0.228–8.105] 0.662a 0.616
A carrier 36 59.0 13 68.5 1.505 [0.504–4.492] 0.462 0.463 C carrier 27 44.3 9 47.3 1.133 [0.404–3.183] 0.812 0.795
Bad
Progno-
sis
CC 22 48.9 9 25.8 1.0 Referent – – GG 29 64.4 15 42.9 1.0 Referent – –
CA 18 40.0 20 57.1 2.716 [0.996–7.409] 0.048 0.045 GC 13 28.9 16 45.7 2.379 [0.910–6.223] 0.075 0.082
AA 5 11.1 6 17.1 2.933 [0.711–12.108] 0.129 0.13 CC 3 6.70 4 11.4 2.578 [0.509–13.046] 0.402a 0.211
A carrier 23 51.1 26 74.2 2.763 [1.061–7.197] 0.035 0.032 C carrier 16 35.6 20 57.1 2.417 [0.977–5.979] 0.054 0.060
TRD: Treatment Resistant Depression. Bad Prognosis: Relapse and TRD. OR: odds ratio. CI: conﬁdence interval. Signiﬁcant P values in bold.
a Fisher exact test.
* p value based on 1000 bootstrap samples.
Table 3
Haplotype frequencies derived from IL18 −137/-607 polymorphisms in remitters and relapsed patients with MDD.
Haplotype Remitter’s Frequency Relapse’s Frequency OR 95% CI p value
GC vs Non GC 0.688 0.531 0.512 0.224–1.168 0.109
CA vs Non CA 0.211 0.406 2.557 1.073–6.093 0.032
O
b
(
r
s
f
In order to identifywhether the different IL18-607C>A and IL18-
137G>C genotypes modulate the peripheral expression of IL18GA vs Non GA 0.100 0.065
R: Odds ratio. CI: Conﬁdence interval.
etween relapse and the presence of IL18 −137/-607CA haplotype
OR=2.557, 95% CI [1.073–6.093], p=0.032). However, after cor-
ecting for multiple comparisons, the association did not retained
igniﬁcance (FDR p=0.093). Regarding TRD, no association was
ound between the evaluated haplotypes and this phenotype.0.600 0.123–2.938 0.525
3.4. Peripheral IL-18 mRNA expressiontranscripts; we evaluated mRNA expression by quantitative real-
time PCR in the peripheral blood of 38 MDD patients. IL18-607C>A
Table 4
Gene Expression Pattern in the IL18-607C>A and IL18-137G>C Genotypes.
SNP Expression CI (95%) P value* Result
IL18-607C>A, CC vs CA+AA 1.855 0.097–89.536 0.029 UP
IL18-137G>C, GG vs GC+CC 1.625 0.081–70.274 0.117 NS
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rI, conﬁdence interval; UP, upregulated; NS, sample group is not different than the
ontrol group.
* Pair Wise Fixed Reallocation Randomization test.
as associated with a 1.855 fold increase in IL18 expression for
A/AAcarriers (1.855;p=0.029;95%CI [0.097–89.536]),whencom-
ared to CC carriers (Table 4). Regarding IL18-137G>C, despite
L18 mRNA levels were more elevated in patients carrying IL18-
37 GC/CC genotypes than in GG genotypes, results were not
tatistically signiﬁcant (1.625; p=0.117; 95% CI [0.081–70.274]).
dditionally, peripheral mRNA expression was not associated with
he last treatment prescribed or treatment response (p>0.05).
. Discussion
Among pro-inﬂammatory cytokines involved in the etiopatho-
enesis of depression, the potential role of IL-18 relies both on
nimal models and clinical studies [19]. Dysregulated IL-18 levels
ave been attributed to several causes, such as neurogenic stimu-
ation or stress [6], but it is still not clear whether IL-18 elevation
ontributes to neuropsychiatric pathologies or whether it is a con-
equence of these disorders [6]. Taken this in consideration, and
iven the fact the IL18 genetic polymorphisms have never been
valuated in AD treatment outcome, we evaluated the role of IL18
romoter SNPs in antidepressant treatment phenotypes.
The results reported herein suggest an association of IL18-
07C>A and IL18-137G>C genetic polymorphisms and the risk
f depression relapse upon AD treatment. Moreover, we also
bserved an association of these polymorphisms with time to
elapse. Regarding the combined effect of the presence of both vari-
nts, haplotype analysis showed an association between relapse
nd the presence of IL18-137/-607 CA haplotype, although it loses
igniﬁcance aftermultiple correction.We also observed a tendency
or Bad Prognosis in patients carrying IL18-607CA/AA, although is
ikely to occur do to the contribution of the relapse phenotype,
ince we haven’t found an association between any of the geno-
ypes and TRD. These results point towards a putative connection
etween IL18 genetic polymorphisms, and a higher risk of depres-
ion relapse.
The idea that IL-18 dysregulation may contribute to depres-
ive symptoms has been supported by other authors. In the study
f Kroes et al., IL18 was one of the twenty-two transcripts dif-
erentially expressed in the neocortex between dominant and
ubordinate mice, undergoing stressful social loss and victory [19].
uthors suggested that this molecule might help submissive ani-
als to better cope with the social stress. This hypothesis was
urther supportedbyanother study, inwhich these two IL18genetic
olymorphisms, rs187238 and rs1946518, were associated with
ncrease susceptibility todepression inpatients previously exposed
o stressful life events [14]. Additionally, it has been observed
hat IL-18 serum levels were signiﬁcantly higher in MDD patients
20]. In that study, authors reported that even when patients were
reated with TCAs (e.g., amitriptyline), the levels of IL-18 were still
igher than those in the control group. This indicates that in some
atients, despite undergoing AD treatment, still exhibit a severe
mmunological stimulation, where IL-18 plays its part. It is possi-
le that this IL-18 immunological dysregulation could be due to the
ontribution of genetic polymorphisms, as we describe herein.
All evidences corroborate our ﬁndings, since we observed that
s187238 and rs1946518 were associated with the relapse ofdepressive symptoms and, moreover, we’ve detected that IL18
was upregulated in patients harboring CA or AA genotypes of
IL18-607C>A. Giedraitis et al. postulated that two SNPs at posi-
tions −607C>A and −137G>C within the IL-18 promoter region
alter the promoter activity [12]. However we have not observed
any statistically signiﬁcant inﬂuence of −137G>C polymorphism
on IL-18 expression, probably because spontaneous and cell line
transcripts are different as suggested by Liang et al., [21]. Our
results are in agreement with the evidences shown by Khripko
and colleagues [22], which reported a higher frequency of A-allele
carriers among persons with a high level of spontaneous IL-18 pro-
duction. Moreover, they also found that the IL-18 production by
LPS-stimulated peripheral blood mononuclear cells (PBMC) was
signiﬁcantly greater in healthy donors carrying the CA genotype
than in those with the CC genotype at the IL18-607 [22]. This is also
in accordance with our ﬁndings since the in our A allele carriers
(CA+AA) group, CA genotype represents approximately 85% of all
group.
The association of IL18-607C>A and IL18-137G>C genetic poly-
morphisms with higher risk of relapse and a lower time to relapse
could be due to inﬂuence of IL-18 in stress induced depressive
symptoms [6]. IL-18 is one of the cytokines (as well as IL-1) acti-
vated by the inﬂammasome complex, a structure recognised to
be a central mediator by which psychological and physical stress-
ors contribute to the development of depression [23]. So, it is
likely that IL18 polymorphisms, by affecting IL-18 levels, would
consequently interfere with downstream events such as the pro-
cessing of pro-IL-18 to IL-18, by the inﬂammasome component
caspase 1 [24], contributing to depression relapse. Likewise, recent
ﬁndings suggest that sustained sad mood, results in a substantial
increase in plasma IL-18 concentration, via -opioid neurotrans-
mission, potentially in response to perceived emotional stress [25],
and additionally, IL-18 is thought to be involved in the regula-
tion of the stress response Hypothalamic–Pituitary–Adrenal (HPA)
axis, known to be dysregulated in depression [6,26]. Besides these
hypotheses, recent literature suggests an alternative possibility, by
which IL-18 would inﬂuence synaptic plasticity and neurogene-
sis, because it is recognised as an activator of JAK–STAT pathway,
through STAT3, in hippocampal cells [27].
To the best of our knowledge, this is the ﬁrst study to evalu-
ate the role of IL18 functional polymorphisms in antidepressant
treatment outcome.We recognize that despite its novelty, this pre-
liminary study holds some limitations. One limitation concerns
sample size, particularly when considering the low number of
patients in the subgroup of CC and GG genotypes that present
relapse. Taken this in account, bootstrapping analysis was per-
formedandvalidatedour results. Additionally, this study is, as far as
we know, the largest one studding the inﬂuence of genetic variants
in antidepressant treatment phenotypes in Portuguese population,
with a long follow up time. Albeit, the statistical power is still suf-
ﬁcient to detect the magnitude of the effect reported regarding
individual polymorphisms. However and since haplotype analy-
sis loses its signiﬁcance after multiple correction, probably due
the small sample size, we recognize that our ﬁndings should be
replicated and validated in larger independent cohorts. A further
limitation stays in the fact that IL18 genotypes have been correlated
with peripheral transcripts levels not with central IL-18 levels, and
we have not controlled patients’ exposure to stressors, a condition
which could inﬂuence mRNA analysis. However, the literature is
consensual about the central role of IL-18 [11], and regarding the
possible link between IL-18 and physical or psychological stress-
ors, future studies may include of the measure of self-perception
of stress, using Perceived Stress Scale or Life Events and Difﬁculties
Schedule.
The ﬁndings reported herein may corroborate the immunoin-
ﬂammatory mechanisms underlying depression; suggesting that
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[19] R.A. Kroes, J. Panksepp, J. Burgdorf, N.J. Otto, J.R. Moskal, Modeling depression:L-18 polymorphisms may play a role in a relapse predisposed phe-
otype. Still, it is likely that other molecules may inﬂuence this
henotype, thus this marker should be integrated with others to
etect the susceptibility of relapse upon AD treatment.
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